• صفحه نخست
  • دومین همایش بین المللی زیست فناوری و توسعه جهانی

کتابچه خلاصه مقالات همایش


دانلود کتابچه

    Novel solution for Cancer treatment problems; Combination of Oncolytic virotherapy and Immunotherapy in cancer treatment

  • Piruz Shadbash,1 Seyed Reza Mohebbi,2,* Seyed Masoud Hosseini,3
    1. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    2. Research Center for Gastroenterology and Liver Diseases, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
    3. Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran


  • Introduction: Oncolytic viruses (OVs) show a new class of therapies that utilizes replicable viruses to cure various types of cancers. Up to now, common oncolytic viruses have been comprised of herpes simplex virus type 1 (HSV-1), oncolytic adenovirus, Newcastle disease virus, oncolytic smallpox virus, and Rhinovirus.
  • Methods: The main attraction to oncolytic viruses (OVs) was as a method of treating cancer based on their distinctive features such as selective tumor proliferation and specific cell toxicity. OVs selectively infect cancer cells and use the host cell apparatus for direct proliferation and lysis of tumor cells.
  • Results: Tumor cell lysis releases tumor-specific antigens that stimulate both the innate immune system and the adaptive immune system. OVs are able to reverse some of the carcinogenic effects and increase antigen processing and delivery, T cell activation, trafficking, and killing, and finally have powerful immunotherapeutic efficacy.
  • Conclusion: The problem with oncolytic virus therapy is the risk of uncontrolled proliferation in vivo. Combining oncolytic virus therapy with other anti-tumor therapies, including chemotherapy and radiation therapy, as well as cancer immunotherapy can be used to target a wider range of tumors and enhance therapeutic efficacy. The combined approach of an oncolytic virus and a PD-1 or PD-L1 blockade can increase antitumor immunity and oncolytic effect. The combination of oncolytic virus therapy and CAR-T immunotherapy has a synergistic effect in cancer patients.
  • Keywords: Ocolytic viruses, treating cancer, CAR-T immunotherapy, cancer patients